Pfizer
Pfizer CEO Albert Bourla to Engage with Activist Investor Starboard Value on Strategic Overhaul
Pfizer, Albert Bourla, Starboard Value, activist investor, pharmaceutical industry, strategic overhaul, post-COVID challenges
Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges
Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination
Pfizer’s Former Executives Back Activist Investor Starboard’s Revamp Plan
Pfizer, Starboard Value, activist investor, Ian Read, Frank D’Amelio, Albert Bourla, pharmaceutical industry, corporate governance
Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees
Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction
Pfizer Generates $2.88 Billion by Selling Off Hundreds of Millions of Haleon Shares
Pfizer, Haleon, share sale, pharmaceutical industry, financial news
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns
Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events
Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies
Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials
AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies
AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology
Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster
Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission
Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15
Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases